COMP <GO>
TGTX vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
TG Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: TGTX 6
— ABBV 9
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: TGTX
LAST: $61.18 (+5.34%) • MKT CAP: $8.89B
options-implied-move
6.50%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
options-implied-move
7.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TGTX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TGTX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.70% | 70.20% | +13.50 | TGTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.00% | 29.00% | -17.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 73.3x | 33.3x | +40.00 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | -0.28% | 3.47% | -3.75 | ABBV | /fcf-yield <GO> |
| Operating Margin | 20.00% | 24.60% | -4.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 6.90% | +61.10 | TGTX | /net-margins <GO> |
| Revenue Growth (YoY) | 87.30% | 8.60% | +78.70 | TGTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.92 | 5.33 | +7.59 | TGTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.50% | 7.40% | -0.90 | TGTX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.7 | 72.8 | -3.07 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 1.15 | -0.28 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.7x | 113.1x | -96.40 | TGTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.89B | $513.86B | -$504.97B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TGTX REV | ABBV REV | TGTX GROSS % | ABBV GROSS % | TGTX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $616.3M | $61.16B | 83.7% | 70.2% | -$25.0M | $17.82B |
| FY 2024 | $329.0M | $56.33B | 88.3% | 70.0% | -$40.6M | $17.83B |
| FY 2023 | $233.7M | $54.32B | 44.0% | 44.0% | -$41.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TGTX // BETA 0.87
ABBV // BETA 1.15